DURHAM, N.C. --(BUSINESS WIRE)--Dec. 22, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience DURHAM, N.C. --(BUSINESS WIRE)--Dec. 16, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the
Agreement includes Europe , Commonwealth of Independent States countries, China , India , parts of Latin America and the Oceania countries DURHAM, N.C. --(BUSINESS WIRE)--Dec. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
